Breaking News

CEL-SCI To Build Manufacturing Site

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

CEL-SCI Corp. has signed a letter of intent with BioProperties, Inc., a privately held real estate firm specialized in the biomedical sector, to acquire and build out a cGMP drug manufacturing facility for CEL-SCI’s cancer product Multikine. CEL-SCI was recently given the green light by the FDA to start a Phase III clinical trial of head & neck cancer patients with Multikine. This manufacturing facility is an integral part of moving Multikine into the Phase III clinical trial and la...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters